Phase II Study of MP-424 in Patients With (Genotype 1b) Hepatitis C

Trial Profile

Phase II Study of MP-424 in Patients With (Genotype 1b) Hepatitis C

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2012

At a glance

  • Drugs Telaprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 04 Sep 2009 Actual patient number (15) added as reported by ClinicalTrials.gov.
    • 04 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Sep 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top